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The combination of halofantrine and primaquine therapies was evaluated as a regimen for achieving radical
cure of falciparum or vivax malaria in Irian Jaya, Indonesia, and compared with combined chloroquine and
primaquine therapies. The patients who volunteered for the study {adult, male, Indonesian immigrants
with no previous exposure to endemic malaria, normal glucose-6-phosphate dehydrogenase (G6PD)
activity, uncomplicated malaria illness, no prior use of antimalarials, and parasitaem ias of 0.001%± 1.0%}
were randomized to receive either halofantrine (24 mg base/kg bodyweight, in three equal doses over 12 h)
or chloroquine (25 mg base/kg bodyweight over 48 h, in doses of 10, 10 and 5 mg base/kg at 24-h
intervals). Each patient also received concurrent daily primaquine (0.5 mg base/kg bodyweight) for 14 days
followed by the same dose on alternate days to day 28. A recurrent parasitaemia during the 28 days of
follow-up constituted drug failure. Of the 40 cases of falciparum malaria and 26 cases of vivax malaria
treated with halofantrine-primaquine, none had a recurrent parasitaemia (100% ef® cacy). In contrast, 20
of 30 patients with falciparum malaria and three of 27 with vivax malaria had recurrent parasitaem ias after
chloroquine-primaquine, giving ef® cacies of 33% and 89%, respectively. Halofantrine-primaquine was
signi® cantly more effective than chloroquine-primaquine against falciparum malaria (P , 0.001) but was
similarly ef ® cacious against vivax malaria (P 5 0.23). On average, fever associated with falciparum or vivax
malaria cleared 17 h faster with halofantrine-primaquine (P , 0.01) although there were no signi® cant
differences (P . 0.4) in parasite-clearance times between the two regimens. The halofantrine-primaquine
regimen was also associated with a more rapid and signi® cant declin e in malaria-related physical
complaints.
Radical cure of malaria, the elimination of
both the blood and tissue stages of the para-
sites by chemotherapeutic agents, is desirable
for prevention of recurrence of infection after
returning from work or travel in places where
relapsing malaria is endemic. In studies that
measure attack rates of malaria, with or with-
out chemoprophylactic intervention, radical
cure is also necessary to eliminate interference
and confounding by relapsing or recrudescing
parasitaemias. There is currently no single
drug with suf® cient safety and dual blood and
tissue schizonticidal properties to achieve this
* E-mail: fryauff@smtp.namru2.go.id; fax: 1 6221 424
4507.
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steriliz ing cure. Most of our studies have used
a combination of three drugs, quinine, doxy-
cycline and primaquine, to achieve radical
cures (Jones et al., 1994; Fryauff et al., 1995;
C. J. Church, T. L. Richie, C. Ohrt, E. Tjitra,
B. Subianto, B. Sandjaya, E. Gomez, J. K.
Baird, D. J. Fryauff and A. L. Richards,
unpubl. obs.; C. K. Ohrt, T. Richie, H. Wid-
jaja, G. D. Shanks, D. J. Fryauff, E. Tjitra, B.
Sandjaja, H. Basri, W. Widjaja, C. Church
and G. Watt, unpubl. obs.). The frequent,
prolonged dosing of quinine and the undesir-
able side effects of this drug compound the
problem of full compliance with therapy. The
drug-related illness which frequently occurs in
otherwise healthy subjects discourages their
voluntary partic ipation and, even among
symptomatic cases, rigid supervision and in-
centives are required to achieve completion of
therapy. The doxycycline component is gener-
ally well-tolerated as long as it is not taken on
an empty stomach but, due to its effect on
bone growth and tooth development, use of
this drug is contra-indicated in children under
the age of 8 years and in females during
pregnancy and nursing (Anon., 1995). Despite
the effectiveness of the current, quinine-based
radical cure, there is interest in developing a
more broadly acceptable drug regimen for
radical cure of chloroquine-resistant malaria.
Halofantrine is an effective and generally
well-to lerated blood schizonticide for use
against chloroquine-resistant Plasmodium falci-
parum in areas where me¯ oquine resistance
has not also developed (Horton and Parr,
1989). Trials have also demonstrated this drug
to be highly effective against P. vivax, includ-
ing the chloroquine-resistant strain s occurring
in Irian Jaya, Indonesia (Parkinson et al., 1989;
Baird et al., 1995a). The use of halofantrine as
an alternative component for achieving radical
cure of malaria was therefore explored; the use
of three, well tolerated doses of halofantrine
over 12 h may be substantially better than
treatment with 12 poorly tolerated doses of
quinine over 4 days given concurrently with
20 doses of doxycycline over 10 days. The aim
of the present study was to see if falciparum
and vivax malaria acquired in Irian Jaya could
be cured radically by using combined halo-
fantrine and primaquine therapies. A `control’
group, given simultaneous chloroquine and
primaquine therapies, was included in order to
estimate properly the effect of primaquine on
patency of parasitaemia after chloroquine
therapeutic failure.
PATIENTS AND METHODS
Study Site and Patients
The study was conducted in the new, trans-
migrant villages of Arso X and XI in north-
eastern Irian Jaya, Indonesia (Baird et al.,
1995b; Fryauff et al., 1995) between January
and July 1993. Most of the approximately
2000 villagers had moved from Java, where the
risk of malaria infection has been about 1
case/10 000 person-years since 1965 (Baird et
al., 1995c). Point prevalences of malaria at the
time of enrolment were 24% in Arso X and
38% in Arso XI, despite the provision of
bednets to all households and the availability
of free chloroquine at the village health clinics.
Enrolment
Overall, 123 Javanese or Balinese males aged
. 15 years, with uncomplicated malaria and
parasitaemias of 0.001% ± 1.0%, quali® ed for
enrolment. Informed consent, a physical
examination and a negative qualitative test for
glucose-6-phosphate dehydrogenase (NADPH
spot test; Sigma) preceded their random as-
signment to one of two treatment groups:
halofantrine-primaquine (HF-PQ) or
chloroquine-primaquine (CQ-PQ).
Treatment and Follow-up
Patients in the HF-PQ group received halo-
fantrine (a total of 24 mg base/kg bodyweight,
in three equal doses over 12 h) and pri-
maquine (0.5 mg base/kg bodyweight daily for
14 days and thereafter on alternate days until
day 28). Those in the CQ-PQ group were
given chloroquine (a total of 25 mg base/kg
bodyweight in three unequal doses over 48 h:
10 mg/kg on Day 0; 10 mg/kg on Day 1; and
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5 mg/kg on Day 2) and primaquine (as
above). Three drug formulations were used:
Halfan Ò (halofantrine; 250 mg base hydrochlo-
ride salt in uncoated tablets, kindly provided
by Dr J. Horton of SmithKline Beecham,
Brentford, U.K.); primaquine (15 mg base as
diphosphate salt in coated tablets; Sano ® -
Winthrop, New York, NY); and Resochin Ò
(chloroquine; 150 mg base as phosphate salt in
uncoated tablets; P. T. Bayer Indonesia,
Jakarta). Every dose was supervised by a
member of the research team. Dry biscuits
and bottled water were provided and patients
were encouraged to eat immediately prior to
or just after consuming the medication. Pa-
tients were visited in their homes daily for the
® rst 2 weeks and then on alternate days until
day 28. Visits consisted of administering
medications, recording answers to a physical-
complaint questionnaire, and making blood
smears for parasitological examination.
Patients suffering treatment failure were of-
fered standard quinine therapy.
Parasitological Examination
Diagnosis of malaria was based upon micro-
scopical examination of Giemsa-stained, thick
and thin, blood ® lms using oil-immersion op-
tics ( 3 1000). At least 300 ocular ® elds were
examined before a slide was considered nega-
tive. The number of asexual parasite s per 200
white blood cells (WBC) was counted and the
number of parasites/ m l blood was then esti-
mated by multip lying this value by 40 (Shute,
1988).
Analysis of Data
The ef® cacy of combined HF-PQ therapies
relative to that of combined CQ-PQ therapies
was determined using Fisher’ s exact test. The
number of hours from startin g treatment
to the point at which parasites became un-
detectable and remained so for at least 2
consecutive days constituted the parasite-
clearance time (PCT). Axillary temperatures
$ 37.5°C indicated fever and fever-clearance
time (FCT) was the number of hours from
startin g treatment to the point at which a
normal temperature of at least two consecutive
days’ duration began. One-way analysis of
variance was used to compare age, weight,
density of parasitaemia, PCT, frequency of
fever and FCT between the two treatment
groups. The incidence density (ID) of physi-
cal complaints not associated with para-
sitaem ia was calculated from the number of
complaints reported per person-month of ob-
servation after discounting day-0 complaints
and those associated with unremitting or re-
current parasitaemias. The decline of all
physical complaints, including those associ-
ated with the initial parasitaemias, was esti-
mated from the proportion of patients
reporting any complaint consistent with
malaria (fever, chills, headache, malaise , ab-
dominal pain, nausea, vomiting, diarrhoea,
arthralgia, myalgia) and the incidence density
per person-day of speci® c complaints reported
on each of test days 0± 7. Proportions and
incidence densitie s were compared using
Fisher’ s exact test or c 2 with Yate’ s correction
applied. Two-tailed P values are reported and
the cut-off for statistica l signi® cance was a P
value # 0.05.
RESULTS
Baseline Characteristics
There were no statistic ally signi® cant differ-
ences between treatment groups at enrolment
in terms of mean age, weight or parasitaemia
(Table 1). More than 92% of the study pa-
tients in each treatment group presented with
malarial symptoms at enrolment and the two
treatment groups were sim ilar in the number
and types of physical complaints reported
(Fig. 1). Malaise, headache, abdominal pain
and nausea were the most frequently reported
physical complaints. Fever was observed in
50% (35/70) of the P. falciparum cases and in
49% (26/53) of the P. vivax.
Comparative Ef® cacy
HF-PQ was completely effective and no treat-
ment failures (persistent or recurrent para-
sitaem ias) occurred among the 40 P.
falciparum and 26 P. vivax cases during 28
days of follow-up (100% ef® cacy). In contrast,
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Fig. 1. Proportions of subjects with malaria-related physical complaints after treatment with halofantrine-pri-
maquine ( h ) or chloroquine-primaquine ( 6 ) and mean numbers of physica l complaints after treatment with
halofantrine-primaquine (Ð ) or chloroquine-primaquine ( ± ± ± ) amongst the P. falciparum (a) and P. vivax
(b) cases.
failures of CQ-PQ therapy occurred within 28
days in 20 of the 30 patients infected with P.
falciparum (33% ef® cacy) and in three of the
27 patients infected with P. vivax (89%
ef® cacy). HF-PQ was signi® cantly more
ef® cacious than CQ-PQ against P. falciparum
(P , 0.001) but sim ilarly ef® cacious against P.
vivax (P 5 0.23). As expected, CQ-PQ was
signi® cantly more ef® cacious against P. vivax
than against P. falciparum (P , 0.001).
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TABLE 2
The means (and ranges) of the parasite- and fever-clearance tim es from the start of therapy with
halofantrine-primaquine (HF-PQ) or chloroquine-primaquine (CQ-PQ)
Parasite-clea rance time (h) Fever-clearance tim e (h)
Infection HF-PQ CQ-PQ P HF-PQ CQ-PQ P
Plasmodium falcipa rum 42 (24± 72) 51 (24± 72) 0.61 28 (24± 72) 45 (24± 72) 0.003
P. vivax 58 (24± 192) 53 (24± 120) 0.44 24 (24) 42 (24± 72) 0.008
Clearance of Parasitaemia and Fever
There was no difference in PCT between the
two treatment regimens for either P. falci-
parum (P 5 0.61) or P. vivax (P 5 0.44). Un-
der either regimen or infection, the mean
PCT was about 50 h (Table 2). In contrast,
FCT in malaria cases treated with HF-PQ was
a mean of 17 h shorter than in those given
CQ-PQ and the difference was signi® cant for
both P. falciparum (P 5 0.003) and P. vivax
(P 5 0.008).
Physical Complaints
In the absence of a patent parasitaemia, physi-
cal complaints in both treatment groups were
infrequent, but the ID per person-week of
malaria-like complaints during the follow-up
period was consistently lower among patients
treated with HF-PQ and collectively were
reported 3.7 ± 4.0 times less often than by cases
of falciparum and vivax malaria treated with
CQ-PQ (P , 0.005; Fig. 2).
Figure 1 shows a comparison of the interval
(daily) proportions of patients registering any
physical complaint consistent with malaria and
the ID/person-day of these speci® c malarial
complaints during test days 0 ± 7, between
treatment groups for each malaria species.
Day-0 physical complaints were similar in the
two treatment groups and most complaints
were registered during the ® rst 48 h of evalu-
ation, before and during the period of parasite
clearance. Within 24 h of having received the
last HF-PQ dose, there was a highly
signi® cant decline in the proportion of pa-
tients reporting any physical complaint (P 5
0.003 for P. falciparum ; P 5 0.02 for P. vivax)
and in the number of speci® c complaints re-
ported by a patient (P , 0.001 for P. falci-
parum ; P 5 0.005 for P. vivax). In contrast,
CQ-PQ treatment required 48± 72 h to pro-
duce a statistic ally signi® cant reduction in
physical complaints.
DISCUSSION
The rationale for the primaquine dosing used
in the present study was that cure of P. vivax
of New Guinea-Irian Jaya origin requires
0.5 mg/kg rather than the standard regimen of
0.25 mg/kg (Clyde and McCarthy, 1977). The
unconventional, alternate-day dosing of
0.5 mg/kg following the 14-day therapy
period was applied as causal prophylaxis, to
prevent re-infection and/or relapse while not
interfering with recrudescence (Arnold et al.,
1954, 1955; Schmidt et al., 1982; Wernsdorfer
and Payne, 1988). It is recognized, however,
that chloroquine and primaquine do appar-
ently act synergistically against P. vivax (Baird
et al., 1995a). Alternate-day use of pri-
maquine, alone, at 0.5 mg base/kg has been
shown to be a well tolerated prophylactic
regimen, affording protective ef® cacies of 74%
against P. falciparum and 90% against P. vivax
among non-immune children and adults living
in Irian Jaya (Baird et al., 1995b).
Combined HF-PQ therapy cleared para-
sitaem ia from all of the study patients and no
treatment failures occurred within 28 days of
beginning treatment, in cases of uncompli-
cated falciparum or vivax malaria acquired in
north-eastern Irian Jaya. This regimen appar-
ently provided a 100% ef® cacious radical cure.
The therapeutic failures seen among similar
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Fig. 2. Incidence densities of physical complaints not associated with patent parasitaemia amongst the P.
falcipa rum (a) and P. vivax (b) cases treated with halofantrine-primaquine ( j ) or chloroquine-primaquine
( 6 ). URI, Upper respiratory infection; (*), signi® cant difference between treatment groups (P , 0.05); (**),
very signi® cant difference between treatment groups (P , 0.005).
patients treated with CQ-PQ prove this be-
cause it shows that primaquine, per se, was not
suf® cient to prevent the appearance of blood-
stage parasite s. The absence of recurrent para-
sitaem ias among patients treated with HF-PQ
therefore demonstrates complete clearance of
the asexual blood stages of P. falciparum and
P. vivax. These results accord with those of
another study in which treatment of P. vivax
with chloroquine or halofantrine, alone, was
14 FRYAUFF ET AL.
compared in the same location in Irian Jaya
(Baird et al., 1995a). In that study, just one of
19 patients treated with halofantrine had a
recurrence of parasitaemia and this single in-
fection, which appeared 25 days post-therapy,
was considered to have been a re-infection or
relapse. Subsequent, more extensive use of
halofantrine alone against P. falciparum or of
halofantrine with primaquine against P. vivax
in the Arso district of Irian Jaya has achieved
comparably high success rates (A. Richards
and T. Richie, unpubl. obs.). A clinical trial of
halofantrine alone in East Kalimantan, In-
donesia, achieved a cure rate for uncompli-
cated falciparum malaria of . 98% (Tjitra et
al., 1992), with FCT and PCT similar to
those seen in the present study when halo-
fantrine and primaquine were used together.
Physical complaints reported in the absence
of detectable parasitaemias were consistently
higher among patients treated with CQ-PQ
than in those given HF-PQ, but these com-
plaints may not have been drug-related. Al-
though there were no differences between
treatment groups in PCT, the slower decline
of malaria-like illness seen in cases treated
with CQ-PQ, and certainly the high failure
rate obtained with this combination against P.
falciparum , indicate that the physical com-
plaints were related more to subpatent para-
sitaem ias in the non-immune population
sampled than to side effects of the drugs.
Primaquine administered at a single daily
dose of 0.5 mg base/kg for 14 days apparently
clears the liver of the tissue stages of P.
falciparum and P. vivax. Although the present
results do not prove this, the results of other
studies demonstrate this effect. The adult reg-
imen of 30 mg daily for 14 days was com-
pletely effective against the Chesson strain of
P. vivax from New Guinea, whereas the 15-
mg regimen has been repeatedly unsuccessfu l
(Clyde and McCarthy, 1977; Rombo et al.,
1987; Jelinek et al., 1995). In a series of four
trials conducted in the Arso region of Irian
Jaya between 1993 and 1995, a total of 651
study volunteers, most of them non-immune
to malaria, and . 25% with patent malaria
infections, were cured radically with a combi-
nation of quinine, doxycycline and primaquine
(Q4D10P14) and no subsequent chemopro-
phylaxis. Not one of these subjects developed
a patent parasitaemia within 2 weeks of the
end of the 14-day therapy (Jones et al., 1994;
Fryauff et al., 1995; C. J. Church, T. L.
Richie, C. Ohrt, E. Tjitra, B. Subianto, B.
Sandjaya, E. Gomez, J. K. Baird, D. J.
Fryauff and A. L. Richards, unpubl. obs.; C.
K.Ohrt, T. Richie, H. Widjaja, G. D. Shanks,
D. J. Fryauff, E. Tjitra, B. Sandjaja, H. Basri,
W. Widjaja, C. Church and G. Watt, unpubl.
obs.). Had any parasitaemia appeared within
the usual 8 ± 14-day incubation period, this
would have marked the failure of primaquine
to clear the liver. Extrapolating from the re-
sults for the study populations involved
(N 5 651) and assuming a conservative two
malaria infections/person-year for the Arso
region, an expected 50 parasitaemias would
have appeared within the collective 50 person-
years of post-rad ical-cure susceptibility which
were contributed by these 651 volunteers if
primaquine had not been an effective causal
prophylactic. The absence of any such para-
sitaem ia is a con® rmation of primaquine’ s po-
tent effect on the liver stages of falciparum
and vivax malaria when dosed at 0.5 mg base/
kg daily for 14 days. Parasitaemias following
the 14-day primaquine regimen, as applied
with halofantrine in the current study, could
only have resulted from re-infections.
Reports of cardiotoxicity associated with the
high-dose halofantrine regimen (Castot et al.,
1993; Nosten et al., 1993) and changes in
recommendations for its use (WHO, 1993)
were only published after the completion of
the present study. While the administration of
halofantrine with food is now contra-ind i-
cated, the provision of food in this study was
intended to protect against the stomach upsets
associated with primaquine use (Clayman et
al., 1952; Clyde, 1981). It now seems clear
that foods may have enhanced the bio-avail-
ability and perhaps the ef® cacy of halofantrine
in the present study (Shanks et al., 1992).
In summary, combined halofantrine and
primaquine therapies achieved radical cure of
falciparum and vivax malaria among non-
immune, G6PD-normal, Indonesian men.
The HF-PQ regimen was associated with
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signi® cantly fewer occasions of physical com-
plaint and/or drug intolerance than were ex-
perienced by patients randomized to CQ-PQ
therapy, and a more rapid decline of malaria
symptoms. These results indicate that the
HF-PQ regimen may be preferred over
quinine-doxycycline-primaquine for radical
cure of malaria among G6PD-normal men
with no contra-indicating, cardiac risk factors.
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cal research.
The opinions or assertions expressed herein
are the private views of the authors and are
not to be construed as representing those of
the U.S. Navy, the Department of Defense, or
the Indonesian Ministry of Health.
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